Hemofiltration as an adjuctive therapy for severe intra-abdominal infection (H-IAI)-a fealibility randomized controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046023

Enrollment

Unknown

Registered

2021-05-02

Start date

2021-05-16

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe intra-abdominal infection

Interventions

Experimental group:Hemofiltration plus convention therapy

Control group:Convention therapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed as severe intra-abdominal infection.

Exclusion criteria

Exclusion criteria: 1. The patient has acute kidney injury and needs emergency renal replacement therapy; 2. The patient or family members do not agree to be included in the group.

Design outcomes

Secondary

Measure	Time frame
28-day mortality;	—

Primary

Measure	Time frame
Organ failure score;	—

Countries

China

Contacts

Public ContactXing Xuezhong

Cancer Hospital of Chinese Academy of Medical Sciences

xingxuezhong@cicams.ac.cn+86 18601141437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026